中國醫藥大學機構典藏 China Medical University Repository, Taiwan:Item 310903500/30625
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 29490/55136 (53%)
造訪人次 : 1565271      線上人數 : 321
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    主頁登入上傳說明關於CMUR管理 到手機版
    請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/30625


    題名: Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma
    作者: Yang, MD;Wu, CC;Chiou, SH;Chiu, CF;Lin, TY;Chiang, IP;Chow, KC
    貢獻者: 附設醫院醫研部;China Med Coll Hosp, Dept Med Res, Taichung 404, Taiwan;China Med Coll Hosp, Dept Surg, Taichung 404, Taiwan;China Med Coll Hosp, Dept Internal Med, Taichung 404, Taiwan;China Med Coll Hosp, Dept Pathol, Taichung 404, Taiwan;China Med Coll, Inst Med Sci, Taichung, Taiwan;Taichung Vet Gen Hosp, Div Gen Surg, Taichung, Taiwan;Natl Chung Hsing Univ, Grad Inst Vet Microbiol, Taichung 40227, Taiwan
    日期: 2003
    上傳時間: 2010-09-24 14:58:53 (UTC+8)
    出版者: PROFESSOR D A SPANDIDOS
    摘要: Purpose : Nasopharyngeal carcinoma (NPC) is a radiosensitive and chemosensitive tumor. This randomized phase III trial compared concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in patients with advanced NPC. Patients and Methods: From December 1993 to April 1999, 284 patients with 1992 American Joint Committee on Cancer stage III to IV (MO) NPC were randomly allocated into two arms. Similar dosage and fractionation of RT was administered in both arms. The investigational arm received two cycles of concurrent chemotherapy wit h cisplatin 20 Mg/m(2)/d plus fluorouracil 400 Mg/m(2)/d by 96-hour continuous infusion during the weeks 1 and 5 of RT. Survival analysis was estimated by the Kaplan-Meier method and compared by the log-rank test. Results: Baseline patient characteristics were comparable in both arms. After a median follow-up of 65 months, 26.2% (37 of 141) and 46.2% (66 of 143) of patients developed tumor relapse in the CCRT and RT-alone groups, respectively. The 5-year overall survival rates were 72.3% for the CCRT arm and 54.2% for the RT-only arm (P =.0022). The 5-year progression-free survival rates were 71.6% for the CCRT group compared with 53.00% for the RT-only group (P =.0012). Although significantly more toixicity was noted in the CCRT arm, including leukopenia and emesis, compliance with the combined treatment was good. The second cycle of concurrent chemotherapy was refused by nine patients and was delayed for a I week for another nine patients. There were no treatment-related deaths in either arm. Conclusion: We conclude that CCRT is superior to RT alone for patients with advanced NPC in endemic areas.
    關聯: ONCOLOGY REPORTS 10(2):271-276
    顯示於類別:[台中附設醫院] 期刊論文

    文件中的檔案:

    沒有與此文件相關的檔案.



    在CMUR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

     


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋